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 To the Editor,
 The COVID-19 vaccines approved so far for use in the 
European Union (EU) include those from Pfizer/BioNTech®, 
Moderna® and AstraZeneca®. Two severe cases of anaphy-
laxis that were resolved after treatment were reported on 
the second day of the vaccination program.1 In the following 
days, an additional potential allergic reaction to the Pfizer/
BioNTech® vaccine was described in the United Kingdom 
(UK) and another eight cases were reported in the United 
States (US).2 This triggered the need to provide recommen-
dations on how to manage the safety concerns that had 
been raised.3
 Regulatory agencies from the EU, US and the UK agree 
that vaccination is contraindicated when there is allergy to 
one of the vaccine components, a severe reaction after the 
first dose or if there is a previous history of a severe allergic 
reaction to vaccines.3 According to the Centers for Disease 
Control and Prevention (CDC), a history of severe allergic 
reaction to an injectable medication will have to be carefully 
evaluated.2
 Polyethylene glycol (PEG), also known as macrogol, 
is an excipient of the Pfizer/BioNTech® and Moderna® vac-
cines. While PEG is considered generally safe for use in 
medical devices and drug formulations, IgE-mediated aller-
gic reactions and anaphylaxis have been reported.4 Poly-
sorbate 80, also known as Tween 80, is a synthetic non-ion-
ic surfactant used as an excipient in the AstraZeneca® vac-
cine, as well as in various drug formulations. Polysorbate 
80 is cross-reactive to PEG and may cause IgE-mediated 
hypersensitivity reactions as well.4
 The fear of a hypersensitivity reaction, particularly 
among patients with pre-existing allergic diseases, may 
lead to unfounded vaccine hesitancy. This may compromise 
the achievement of herd immunity, and thus unnecessar-
ily extend the pandemic, with devastating social, economic 
and health consequences.
 We highlight that there is absolutely no indication for car-
rying out a systematic preventive allergy study, prior to the 
administration of a COVID-19 vaccine, to any individual with 
allergic rhinitis and/or asthma and/or eczema. These vac-
cines are contraindicated in case of allergy to the COVID-19 
vaccine components (namely PEG and polysorbate 80) or 
in case of anaphylaxis after administration of the first dose. 
In case of previous anaphylaxis to other vaccines, severe 
or multiple drug allergy, mastocytosis/mast cell activation 
syndromes or idiopathic anaphylaxis, precautions should 
be taken and an immunoallergy evaluation must take place 
before vaccination in a hospital setting, but these are not 
considered contraindications. There is already evidence 
that the administration of COVID-19 vaccines with premedi-
cation is safe in patients with mastocytosis and mast cell 
activation symptoms, including anaphylaxis.5
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